Kevin J. Leary
Research Subjects
Kevin J. Leary has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Bryan Smith
United States Army Medical Materiel Development Activity, 1430 Veterans Drive, Fort Detrick, Maryland 21702, USA
1 shared publication Caron Kerr
United States Army Medical Materiel Development Activity, Fort Detrick, Maryland; Uniformed Services University of the Health Sciences, Bethesda, Maryland; Indiana University School of Medicine, Indianapolis, Indiana; Acufocus, Inc., Irvine, California; GlaxoSmithKline Research and Development, Greenford, Middlesex, United Kingdom; Chiltern International Ltd., Early Phase Unit, Slough, Berkshire, United Kingdom; Walter Reed Army Institute of Research, Silver Spring, Maryland
1 shared publicationColin Ohrt
United States Army Medical Materiel Development Activity, Fort Detrick, Maryland; Uniformed Services University of the Health Sciences, Bethesda, Maryland; Indiana University School of Medicine, Indianapolis, Indiana; Acufocus, Inc., Irvine, California; GlaxoSmithKline Research and Development, Greenford, Middlesex, United Kingdom; Chiltern International Ltd., Early Phase Unit, Slough, Berkshire, United Kingdom; Walter Reed Army Institute of Research, Silver Spring, Maryland
1 shared publicationCorina van de Pol
United States Army Medical Materiel Development Activity, Fort Detrick, Maryland; Uniformed Services University of the Health Sciences, Bethesda, Maryland; Indiana University School of Medicine, Indianapolis, Indiana; Acufocus, Inc., Irvine, California; GlaxoSmithKline Research and Development, Greenford, Middlesex, United Kingdom; Chiltern International Ltd., Early Phase Unit, Slough, Berkshire, United Kingdom; Walter Reed Army Institute of Research, Silver Spring, Maryland
1 shared publicationD. Craig Brater
United States Army Medical Materiel Development Activity, Fort Detrick, Maryland; Uniformed Services University of the Health Sciences, Bethesda, Maryland; Indiana University School of Medicine, Indianapolis, Indiana; Acufocus, Inc., Irvine, California; GlaxoSmithKline Research and Development, Greenford, Middlesex, United Kingdom; Chiltern International Ltd., Early Phase Unit, Slough, Berkshire, United Kingdom; Walter Reed Army Institute of Research, Silver Spring, Maryland
1 shared publicationDaoqin Bi
United States Army Medical Materiel Development Activity, Fort Detrick, Maryland; Uniformed Services University of the Health Sciences, Bethesda, Maryland; Indiana University School of Medicine, Indianapolis, Indiana; Acufocus, Inc., Irvine, California; GlaxoSmithKline Research and Development, Greenford, Middlesex, United Kingdom; Chiltern International Ltd., Early Phase Unit, Slough, Berkshire, United Kingdom; Walter Reed Army Institute of Research, Silver Spring, Maryland
1 shared publication
Latest Publications
- Open Access
- 1 August 2012
- Published by Springer Nature in Malaria Journal
- Vol. 11 (1) , 255
Pharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: Phase 1b study
Severe malaria results in over a million deaths every year, most of them in children aged less than five years and living in sub-Saharan Africa. Injectable artesunate (AS) was recommended as initial treatment for severe malaria by WHO in 2006. The Walter Reed Army Institute of Research (WRAIR) has been developing a novel good manufacturing practice (GMP) injection of AS, which was approved by the US FDA for investigational drug use and distribution by the CDC.
- 1 August 2012
- Published by Springer Nature in Malaria Journal
- Vol. 11 (1) , 255
Open AccessPharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: Phase 1b study
Severe malaria results in over a million deaths every year, most of them in children aged less than five years and living in sub-Saharan Africa. Injectable artesunate (AS) was recommended as initial treatment for severe malaria by WHO in 2006. The Walter Reed Army Institute of Research (WRAIR) has been developing a novel good manufacturing practice (GMP) injection of AS, which was approved by the US FDA for investigational drug use and distribution by the CDC.
- 1 August 2009
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 81 (2) , 356-362
A Randomized, Double-Blind, Safety and Tolerability Study to Assess the Ophthalmic and Renal Effects of Tafenoquine 200 mg Weekly versus Placebo for 6 Months in Healthy Volunteers
A randomized, double-blind, placebo-controlled study was conducted to assess the effect of tafenoquine, 200 mg weekly for 6 months on ophthalmic and renal safety. This trial was carried out after observations in previous clinical trials that tafenoquine may be associated with the development of corneal deposits and elevations in serum creatinine. In 120 healthy volunteers who received tafenoquine or placebo in a 2:1 randomization, there was no effect on night vision or other ophthalmic indices measured. Persons taking tafenoquine also showed no difference in mean change in glomerular filtration rate (GFR, mL/s/1.73 m2) after 6 months of dosing, with a treatment difference of −0.061 (95% confidence interval, −0.168, 0.045), and non-inferiority margin of −0.247 mL/s/1.73 m2. Tafenoquine was well tolerated over the course of the study. The results of this study showed no clinically significant effects of tafenoquine on ophthalmic or renal function, and support its continued development as an antimalarial drug.
- 1 August 2009
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 81 (2) , 356-362
A Randomized, Double-Blind, Safety and Tolerability Study to Assess the Ophthalmic and Renal Effects of Tafenoquine 200 mg Weekly versus Placebo for 6 Months in Healthy Volunteers
A randomized, double-blind, placebo-controlled study was conducted to assess the effect of tafenoquine, 200 mg weekly for 6 months on ophthalmic and renal safety. This trial was carried out after observations in previous clinical trials that tafenoquine may be associated with the development of corneal deposits and elevations in serum creatinine. In 120 healthy volunteers who received tafenoquine or placebo in a 2:1 randomization, there was no effect on night vision or other ophthalmic indices measured. Persons taking tafenoquine also showed no difference in mean change in glomerular filtration rate (GFR, mL/s/1.73 m2) after 6 months of dosing, with a treatment difference of −0.061 (95% confidence interval, −0.168, 0.045), and non-inferiority margin of −0.247 mL/s/1.73 m2. Tafenoquine was well tolerated over the course of the study. The results of this study showed no clinically significant effects of tafenoquine on ophthalmic or renal function, and support its continued development as an antimalarial drug.